RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers Including Brain, Pancreatic and Liver
3B Pharmaceuticals enters into a Global Exclusive Licensing Agreement for its FAP-Targeting Peptide Technology
3B Pharmaceuticals hosts industry symposium on radiopharmaceutical innovation alliances and supports the 6th Theranostic World Congress
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
Boehringer Ingelheim and 3B Pharmaceuticals sign drug discovery collaboration
Ipsen and 3BP announce First Patient Dosed in Phase I/II study for first-in-class radionuclide (IPN01087)
3B Pharmaceuticals and Sovicell introduce a novel service offering for plasma protein binding analysis
KNAUER and 3B Pharmaceuticals showcase novel affinity purification process for camelid antibodies
Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology